Search - tctmd.com

Displaying 21 - 40 of 165

Sort: Relevancy | Date

Presentation TCT 2019

Clinical Trial Updates: Deep Vein Arterialization

Presenter: Steven Kum

September 25, 2019

Presentation TCT 2019

Clinical Trial Updates: BEST-CLI, BASIL-2 and BASIL-3

Presenter: Matthew Menard

September 25, 2019

Presentation TCT 2019

Modern Outcomes for Rutherford 6 Patients: How to Avoid Primary Amputation

Presenter: Peter Schneider

September 25, 2019

Presentation TCT 2019

What Is Optimal Medical Therapy for CLI? Can We Move the Needle With Drugs Alone?

Presenter: Marc Bonaca

September 25, 2019

Presentation TCT 2019

Surgical Therapy: Indications for Surgery First for CLI

Presenter: Peter Schneider

September 25, 2019

Presentation TCT 2019

Featured Lecture: CLI Epidemiology and Clinical Burden

Presenter: Schuyler Jones

September 25, 2019

Presentation TCT 2019

CTO Crossing 5: Case Examples of Below-the-Ankle Access and Pedal Loop Reconstruction

Presenter: Osamu Iida

September 25, 2019

Presentation TVT 2019

Comparing the Low-Risk Trials (PARTNER 3 and Medtronic Low-Risk)

Presenter: Martin Leon

June 13, 2019

Presentation TVT 2019

The PARTNER 3 Low-Risk Randomized Trial

Presenter: Susheel Kodali

June 13, 2019

Presentation TVT 2019

Incidence, Trends, Risk Factors, and Comparison With Surgery for Early Stroke After TAVR: Reports From PARTNER and the TVT Registry (in High- and Intermediate-Risk Patients)

Presenter: Samir Kapadia

June 13, 2019

Presentation TCT 2018

PARTNER VALVE-IN-VALVE: Late Follow-up After Treatment of Failing Surgical Aortic Bioprosthetic Valves With a Balloon-Expandable Transcatheter Heart Valve

Presenter: John G. Webb

September 23, 2018

Presentation The Structural Heart Disease Summit 2018

Strokes After Transfemoral TAVR vs SAVR: A Propensity-Matched Analysis From the PARTNER Trial

Presenter: Eberhard Grube, Tamim Nazif, Chetan P. Huded

June 21, 2018

Presentation TCT 2017

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Presenter: Pamela S. Douglas

November 01, 2017

Presentation TCT 2017

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Presenter: Patrick W. Serruys, David J. Cohen

October 31, 2017

Presentation TCT 2017

Important Clinical Lessons From the VIVID Registry and the PARTNER Experience

Presenter: John G. Webb

October 30, 2017

Presentation TCT 2017

The PARTNER 3 Low-risk Trial

Presenter: Michael J. Mack

October 30, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

Presentation TCT 2017

Take-home Messages and Closing Comments

Presenter: Amal Kumar Banerjee, Rabin dra Nath Chakraborty

October 29, 2017

Presentation TCT 2017

Clinical Case #4: A Complex and High-Risk PCI

Presenter: Anibal A. Damonte, Alejandro O. Palacios, Alejandro Cherro

October 29, 2017

Presentation TCT 2017

Resting Pd/Pa vs FFR for Predicting Coronary Events

Presenter: Gary S. Mintz, Seung-Jung Park, Jung-Min Ahn

October 29, 2017

Advertisement

Clinical Trial Updates: Deep Vein Arterialization

Clinical Trial Updates: BEST-CLI, BASIL-2 and BASIL-3

Modern Outcomes for Rutherford 6 Patients: How to Avoid Primary Amputation

What Is Optimal Medical Therapy for CLI? Can We Move the Needle With Drugs Alone?

Surgical Therapy: Indications for Surgery First for CLI

Featured Lecture: CLI Epidemiology and Clinical Burden

CTO Crossing 5: Case Examples of Below-the-Ankle Access and Pedal Loop Reconstruction

Comparing the Low-Risk Trials (PARTNER 3 and Medtronic Low-Risk)

The PARTNER 3 Low-Risk Randomized Trial

Incidence, Trends, Risk Factors, and Comparison With Surgery for Early Stroke After TAVR: Reports From PARTNER and the TVT Registry (in High- and Intermediate-Risk Patients)

PARTNER VALVE-IN-VALVE: Late Follow-up After Treatment of Failing Surgical Aortic Bioprosthetic Valves With a Balloon-Expandable Transcatheter Heart Valve

Strokes After Transfemoral TAVR vs SAVR: A Propensity-Matched Analysis From the PARTNER Trial

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Important Clinical Lessons From the VIVID Registry and the PARTNER Experience

The PARTNER 3 Low-risk Trial

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Take-home Messages and Closing Comments

Clinical Case #4: A Complex and High-Risk PCI

Resting Pd/Pa vs FFR for Predicting Coronary Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content